

View larger version (52K):
[in a new window]
|
Figure 2. Effects of PGE2, various EP agonists, or cAMP-elevating agents on MMP-3 levels and activities in IL-1ß-stimulated HGF derived from healthy gingiva. Cells were stimulated with vehicle or 2 ng/mL IL-1ß in the presence of 1 µM indomethacin, with or without various doses of PGE2, 17 phenyl- -trinor PGE2, butaprost, and ONO-AE-1329 for caseinolytic activity assay (A,B,C,D), or with or without various doses of PGE2, 1 µM of 17 phenyl- -trinor PGE2, 1 µM of butaprost, 1 µM of ONO-AE1-329, 100 µM of dibutyryl cAMP (dbcAMP), and 10 µM of forskolin (FS) for MMP-3 protein level assay (E,F,G,H), for 72 hrs. After incubation, caseinolytic activities and MMP-3 protein levels in the culture media were assayed by casein zymography and enzyme-linked immunosorbent assay, respectively, as described in MATERIALS & METHODS. Values are mean ± SD (n = 4). Data are representative of 3 separate experiments. *Significantly different from indomethacin+1L-1ß (p < 0.05). **Significantly different from indomethacin+1L-1ß (p < 0.0001). ***Significantly different from indomethacin+1L-1ß (p < 0.001). #Significantly different from indomethacin+1L-1ß (p < 0.05). $Significantly different from indomethacin+1L-1ß (p < 0.05). $$Significantly different from indomethacin+1L-1ß (p < 0.005). @Significantly different from indomethacin+1L-1ß (p < 0.0001).
|